Landmark Pancreatic Cancer Breakthrough: New Daily Pill Nearly Doubles Survival Time for Advanced Patients

Health and Medical News Journalist

CHICAGO — In what is being hailed as a potentially transformative milestone for oncology, researchers announced at the 2026 Annual Meeting of the American Society of Clinical Oncology (ASCO) that a new, once-daily oral medication nearly doubles the survival time for patients fighting advanced metastatic pancreatic cancer.

The breakthrough findings from the highly anticipated Phase 3 RASolute 302 trial, simultaneously published in the New England Journal of Medicine, reveal that the experimental drug daraxonrasib achieved a median overall survival of 13.2 months. In comparison, patients receiving standard second-line chemotherapy survived a median of 6.6 to 6.7 months. This represents a staggering 60% reduction in the risk of death, marking the first time a targeted therapeutic agent has shown such a decisive survival advantage over conventional chemotherapy in this advanced treatment setting.

Why This Matters: Confronting Oncology’s Most Formidable Challenge

Pancreatic cancer has long maintained a reputation as one of the deadliest malignancies. According to data from the American Cancer Society and the National Cancer Institute’s SEER program, the overall five-year relative survival rate for pancreatic cancer stands at a sobering 13%.

The World Health Organization (WHO) notes that the disease is exceptionally difficult to manage because symptoms typically emerge only after the cancer has metastasized to distant organs. Early warning signs are frequently vague and easily misattributed to less severe ailments. These include:

• Abdominal or back pain

• Unexplained weight loss

• Jaundice (yellowing of the skin and eyes)

• Digestive complications

Consequently, a vast majority of patients are diagnosed at a late, inoperable stage. Globally, the burden of this disease is intensifying; incidence has more than doubled in recent decades. The WHO reported an estimated 510,922 new cases and 467,409 deaths in 2022 alone, positioning it as the sixth leading cause of cancer-related mortality worldwide.

In India, the clinical landscape reflects a steady rise in pancreatic cancer diagnoses. Oncologists attribute this uptick to an aging population, rising rates of obesity and diabetes, tobacco use, and enhanced diagnostic capabilities. Because the disease is overwhelmingly caught at advanced stages, the introduction of a highly effective secondary therapy holds profound public health implications for patients who have run out of standard therapeutic options.

How Daraxonrasib Works: Cracking the “Undruggable” KRAS Target

Developed by Revolution Medicines, daraxonrasib belongs to an innovative class of therapeutics known as RAS(ON) inhibitors. To understand its significance, one must understand the biology of the tumor: more than 90% of pancreatic ductal adenocarcinomas (mPDAC) are driven by mutations in the KRAS gene, an oncogene that acts as an unyielding “on” switch for cancer cell growth and survival.

For more than 40 years, structural biologists deemed KRAS to be entirely “undruggable.” The protein’s spherical surface lacked deep, accessible binding pockets where traditional small-molecule drugs could latch on.

“The word ‘undruggable’ was an inventory of tools taken at a specific moment in time. The tools changed, and the verdict followed,” explained researchers from the Dana-Farber Cancer Institute. They noted that a confluence of technological breakthroughs over the last decade—including cryo-electron microscopy, AI-assisted molecular design, fragment-based discovery, and mass-spectrometry proteomics—finally brought the elusive KRAS protein into computational reach.

Unlike first-generation KRAS inhibitors that only target a singular mutation subtype (such as KRAS G12C), daraxonrasib is designed as a multiselective inhibitor. It binds to the active, “on” state of a broader range of RAS variants. This wide-spectrum activity explains why the drug has demonstrated such robust efficacy across a heterogeneous population of patients with diverse mutation profiles.

Trial Design and Key Findings

The Phase 3 RASolute 302 trial evaluated approximately 500 patients diagnosed with previously treated metastatic pancreatic ductal adenocarcinoma—the most prevalent form of pancreatic cancer. All participants had experienced disease progression despite undergoing first-line chemotherapy. Patients were randomized to receive either a daily oral dose of daraxonrasib or standard physician’s choice second-line chemotherapy.

The resulting data triggered a rare standing ovation from attendees at the ASCO meeting, a reaction signaling a massive paradigm shift for practicing oncologists.

Phase 3 RASolute 302 Trial Outcomes

“These results are landscape-changing for metastatic pancreatic cancer patients with a KRAS mutation,” said Dr. Rachna Shroff, chief of hematology and oncology at the University of Arizona Cancer Center, in an official statement released by ASCO. “We are seeing unprecedented survival and efficacy in second-line treatment with an expected safety profile.”

Alan Sandler, Chief Development Officer at Revolution Medicines, emphasized the historic nature of the cohort’s longevity, noting that this study represents the first time any clinical trial has enabled a median survival exceeding one year for advanced pancreatic cancer patients in this setting.

Improved Tolerability: A Reprieve From Toxic Chemotherapy

Beyond extending life, the trial highlighted a vital benefit for patient quality of life: daraxonrasib proved significantly less toxic than traditional cytotoxic chemotherapy.

While adverse events were common, they were largely manageable and predominantly low-grade. The most frequently observed side effects included:

• Mild-to-moderate skin rash

• Diarrhea

• Nausea and vomiting

• Fatigue

• Inflammation of the oral mucosa (mouth sores)

Crucially, severe treatment-related side effects (Grade 3 or higher) occurred in 43.6% of the daraxonrasib group compared to 57.5% of those on chemotherapy, resulting in substantially fewer patients abandoning their treatment due to toxicity.

“The drug’s impact was so broadly strong, in part, because enrollees who got daraxonrasib felt better almost immediately,” observed Dr. Pashtoon Kasi, a gastrointestinal oncology specialist at City of Hope and a primary study investigator. For individuals managing the heavy physical toll of advanced pancreatic cancer, trading intravenous hospital infusions for a daily, more tolerable oral pill represents a major victory.

Expert Perspectives: Cautious Optimism

Independent oncology experts have greeted the data with enthusiastic, yet measured, optimism.

Dr. Zev Wainberg, Director of the UCLA Clinical Translational Oncology Program, who played a central role in evaluating the drug, tempered expectations appropriately: “Although it does not eradicate the cancer, this represents a substantial advancement.”

Dr. Brian Wolpin of the Dana-Farber Cancer Institute, who presented the findings at ASCO, strongly advocated for daraxonrasib to be recognized immediately as “a new standard of care” for previously treated metastatic pancreatic cancer. Dr. Wolpin noted that the next clinical frontier involves moving the drug into first-line settings, exploring whether its dramatic tumor-shrinking capabilities could downstage tumors enough to make some advanced patients eligible for potentially curative surgical resections.

Outside experts agree on the magnitude of the trial’s success. Dr. Benjamin Weinberg, an associate professor of medicine at Georgetown University Lombardi Comprehensive Cancer Center, characterized the data as “very impressive.” Meanwhile, Dr. Robert Balder-Anderson, Director of the Abramson Cancer Center at the University of Pennsylvania, remarked: “We have to remind ourselves that this is truly unprecedented.”

Regulatory Pathway and Future Horizons

Recognizing the urgent unmet medical need, the U.S. Food and Drug Administration (FDA) has acted with historic speed. Following an official request on April 28, 2026, the FDA signed off on an Expanded Access Program (EAP) on April 30, 2026. This pathway allows qualifying patients who cannot participate in clinical trials and have exhausted standard options to access daraxonrasib before formal commercial approval.

Furthermore, the drug has been granted a Commissioner’s National Priority Voucher. This designation compresses the typical 10-to-12-month FDA review cycle into a matter of months. Revolution Medicines has announced intentions to submit its formal New Drug Application (NDA) under this expedited track imminently.

The therapeutic implications of this breakthrough also extend well beyond the pancreas. Because RAS mutations heavily drive other lethal malignancies—including roughly 30% of non-small cell lung cancers and up to 50% of colorectal cancers—the success of this RAS(ON) inhibitor provides a validated blueprint that could rapidly accelerate targeted drug discovery across a wider oncology landscape.

Limitations and Considerations for Patients

Despite the extraordinary enthusiasm, medical authorities urge families to remain realistic. Daraxonrasib is a highly effective control mechanism, but it is not a cure.

Over time, cancer cells are notoriously adaptive; tumors eventually develop secondary mutations or activate alternative cellular pathways to bypass the blocked KRAS signaling chain, leading to drug resistance. Long-term follow-up studies remain critical to determine how long these survival benefits endure.

Additionally, because the trial specifically enrolled patients whose disease had already progressed past first-line chemotherapy, its efficacy as an initial treatment remains unproven. Clinicians also emphasize that while the trial spanned centers across North America, Europe, and Asia, ongoing diverse real-world data collection will be vital to ensure these survival metrics translate seamlessly across all global populations.

For now, patients and families facing an advanced diagnosis should consult their treating oncologists to see if they meet the criteria for the FDA’s newly opened Expanded Access protocol or ongoing clinical trials. While it is not yet available for routine pharmacy prescription, daraxonrasib has undeniably turned a page in cancer history, proving that oncology’s most famously “undruggable” target can finally be cornered.

Medical Disclaimer

Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.

References

• https://www.ndtv.com/health/pancreatic-cancer-breakthrough-new-daily-pill-daraxonrasib-doubles-survival-time-for-advanced-patients-11579078